Clinical and laboratory assessments at baseline and after 3 and 12 months of etanercept treatment. Values are mean ± SD or median (range).
| Assessment | Baseline | 3 Months | p* | 12 Months | p** |
|---|---|---|---|---|---|
| Males (n = 68) | |||||
| BASDAI (range 0–10) | 6.0 ± 1.7 | 3.0 ± 2.0 | 0.000 | 3.1 ± 2.3 | 0.000 |
| ESR, mm/h | 19 (2–101) | 4 (2–51) | 0.000 | 5 (2–50) | 0.000 |
| CRP, mg/l | 15 (2–99) | 3 (2–56) | 0.000 | 3 (2–56) | 0.000 |
| ASDAS | 3.8 ± 0.9 | 1.9 ± 0.8 | 0.000 | 2.1 ± 1.1 | 0.000 |
| Physician GDA (range 0–10) | 6 (1–9) | 2 (0–5) | 0.000 | 1 (0–8) | 0.000 |
| Patient GDA (range 0–10) | 7 (1–10) | 3 (0–9) | 0.000 | 2 (0–10) | 0.000 |
| BASFI (range 0–10) | 6.0 ± 2.0 | 3.8 ± 2.4 | 0.000 | 3.6 ± 2.6 | 0.000 |
| MMP-3, ng/ml | 13.6 (4.3–47.5) | 13.1 (5.0–35.7) | 0.016 | 12.7 (3.3–37.6) | 0.053 |
| Females (n = 24) | |||||
| BASDAI (range 0–10) | 6.8 ± 1.8 | 3.8 ± 1.9 | 0.000 | 3.6 ± 2.0 | 0.000 |
| ESR, mm/h | 27 (5–67) | 15 (2–40) | 0.000 | 17 (3–46) | 0.012 |
| CRP, mg/l | 12 (2–55) | 4 (2–24) | 0.001 | 6 (2–196) | 0.019 |
| ASDAS | 4.1 ± 0.5 | 2.5 ± 1.0 | 0.000 | 2.6 ± 1.1 | 0.000 |
| Physician GDA (range 0–10) | 7 (1–8) | 2 (0–7) | 0.000 | 1 (0–9) | 0.001 |
| Patient GDA (range 0–10) | 8 (2–10) | 4 (0–10) | 0.002 | 4 (1–9) | 0.004 |
| BASFI (range 0–10) | 5.7 ± 2.2 | 3.2 ± 2.1 | 0.000 | 3.1 ± 2.3 | 0.001 |
| MMP-3, ng/ml | 5.9 (1.8–26.2) | 5.6 (2.4–11.0) | 0.983 | 7.2 (3.3–14.6) | 0.191 |